BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12678750)

  • 1. Antimitotic peptides and depsipeptides.
    Hamel E; Covell DG
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):19-53. PubMed ID: 12678750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of antimitotic peptides and depsipeptides with tubulin.
    Hamel E
    Biopolymers; 2002; 66(3):142-60. PubMed ID: 12385035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
    Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
    Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
    Mitra A; Sept D
    Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
    Bai R; Friedman SJ; Pettit GR; Hamel E
    Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
    Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
    J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
    Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
    Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
    Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
    Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antimitotic agents on tubulin-nucleotide interactions.
    Correia JJ
    Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiochemical aspects of tubulin-interacting antimitotic drugs.
    Correia JJ; Lobert S
    Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
    Mooberry SL; Leal RM; Tinley TL; Luesch H; Moore RE; Corbett TH
    Int J Cancer; 2003 Apr; 104(4):512-21. PubMed ID: 12584751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FR901228 causes mitotic arrest but does not alter microtubule polymerization.
    Sandor V; Robbins AR; Robey R; Myers T; Sausville E; Bates SE; Sackett DL
    Anticancer Drugs; 2000 Jul; 11(6):445-54. PubMed ID: 11001385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
    FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule-disrupting effects of gallium chloride in vitro.
    Perchellet EM; Ladesich JB; Collery P; Perchellet JP
    Anticancer Drugs; 1999 Jun; 10(5):477-88. PubMed ID: 10477168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; EtiƩvant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
    Weiss C; Figueras E; Borbely AN; Sewald N
    J Pept Sci; 2017 Jul; 23(7-8):514-531. PubMed ID: 28661555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
    Bai R; Durso NA; Sackett DL; Hamel E
    Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.